How long would you continue second line maintenance PARP inhibitor in a patient with recurrent stage IV BRCA+ ovarian cancer who had CR and remains NED?  

Do you extrapolate from first line maintenance studies for duration of therapy?



Answer from: Medical Oncologist at Academic Institution

Answer from: at Academic Institution

Answer from: Medical Oncologist at Community Practice